Evaluating Ovarian Toxicity Outcomes Following Immunotherapy in Patients With Triple-Negative Bre… (NCT07527819) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Evaluating Ovarian Toxicity Outcomes Following Immunotherapy in Patients With Triple-Negative Breast Cancer (TNBC)
Australia75 participantsStarted 2026-04-08
Plain-language summary
This study aims to collect information about the effects of chemotherapy combined with immunotherapy (immune checkpoint inhibitors) for early-stage triple-negative breast cancer (TNBC) on ovarian function and fertility.
You may be eligible for this study if you have been diagnosed with early-stage TNBC and are planning to receive neoadjuvant chemotherapy combined with immunotherapy before surgery. Additional eligibility criteria apply.
Participants who choose to enroll will be asked to complete questionnaires and provide blood samples before and after treatment to measure hormone levels related to ovarian function. Information about menstrual patterns, fertility preservation discussions, and reproductive health will also be collected. Some participants may undergo ultrasound assessments to evaluate ovarian reserve and endometrial thickness. Follow-up will continue for up to 24 months after treatment to assess long-term ovarian function.
No additional or experimental cancer treatments will be provided as part of this study. This is an observational study only, and participants will receive standard cancer treatment as recommended by their treating team.
It is hoped this research will provide important information about the potential effects of chemotherapy and immunotherapy on ovarian health and fertility in women receiving treatment for early-stage TNBC.
Who can participate
Age range18 Years – 42 Years
SexFEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Patient has provided written informed consent using the FERTILE Patient Information and Consent form (PICF)
✓. Early-stage TNBC (definition determined as per clinicians' discretion)
✓. Female patients between 18 and 42 years of age
✓. Planned to receive at least one dose of neoadjuvant chemotherapy-ICI with a PD-(L)1 inhibitor including but not limited to pembrolizumab, atezolizumab, durvalumab or nivolumab
✓. Planned to receive gonadotrophin releasing hormone (GnRH) agonist with neoadjuvant chemotherapy
Exclusion criteria
✕. Previous removal of both ovaries or ovarian ablation (such as bilateral ovarian radiotherapy)
✕. Patients who have previously received immunotherapy or chemotherapy prior to registration
✕. Receiving or planned to receive adjuvant endocrine therapy Note: patients using GnRH agonist for POI prevention are not excluded
✕
What they're measuring
1
Premature Ovarian Insufficiency (POI) at 24 months after cessation of neoadjuvant chemotherapy-ICI
Timeframe: 24 months (±12 weeks) after cessation of neoadjuvant chemotherapy-ICI
✕. Presence of any psychological, social, geographical, or other condition for which, in the opinion of the site Investigator, participation would not be in the best interest of the patient (e.g., compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments